Marreaud, Sandrine
European Organisation for Research and Treatment of Cancer
2 papers on CoChatORCID 0000-0002-3205-3858
Most cited papers
- Verified
Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine
Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers
Cited by 1,906
- Verified
Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.
Eggermont, A. M. M., Kicinski, M., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A. M., Lichinitser, M., Khattak, M., et al. (2019) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management
Cited by 14
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free